We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
"In 2017 only one company was generating more than 10% of its overall revenue from the orphan and rare dermatology therapy area. However, by 2024 there will be several companies generating more than 85% of their revenue from the therapy area.”